H.C. Wainwright analyst Ram Selvaraju initiated coverage with a Buy rating on Inovio Pharmaceuticals (INO) today and set a price target of $13. The company’s shares closed yesterday at $5.22.
Selvaraju observed:
“Our 12-month price target is derived from a market value of the firm at $1.4B, which includes a discounted cash flow based asset value for 15% discount rate, 2% terminal growth rate and 80% probability of success.”
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -13.3% and a 24.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Aerpio Pharmaceuticals Inc.
Inovio Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $10.25, which is a 96.4% upside from current levels. In a report issued on November 26, Maxim Group also maintained a Buy rating on the stock with a $8 price target.
.
See today’s analyst top recommended stocks >>
Based on Inovio Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $25.02 million. In comparison, last year the company had a GAAP net loss of $34.13 million.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. Last month, Peter Kies, the CFO of INO sold 10,001 shares for a total of $52,805.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.